Simon analyze commercial insurance claims for approximately 537,000 patients who initiated GLP-1 treatment between 2017 and 2022
(2025, August 6)
The obesity pharmacotherapy space continues to evolve with additional therapies in the pipeline including maritide (a GLP-1RA/GIP antagonist), cagrisema (a GLP-1RA/amylin RA), and retatrutide (a GLP-1RA /GIP/glucagon RA) which have shown promise in clinical trials [76]
Unlike approved agents such as semaglutide (Wegovy) or tirzepatide (Zepbound), retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the United Kingdom
Choose quantity Peptide checkout Lyophilized vials can remain stable before reconstitution when stored as directed
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone
